AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02379520 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HPV Specific T Cells
Description: Dose escalation study with 5 dose levels: DL1-1×10\^7 cells/m2, DL2-3×10\^7 cells/m2, and DL3-1×10\^8 cells/m2, DL4- 2 to 3×10\^8 cells/m2, DL5- 0.8 to 1×10\^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion \& nivolumab \& HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) \& no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level.
Study NCT01411592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multilink
Description: After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
Study NCT01411592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Panavia 21 TC
Description: After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
Study NCT00598169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
Study NCT00598169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2.
Study NCT00598169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
Study NCT00598169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
Study NCT00598169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2.
Study NCT00598169 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
Study NCT00598169 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
Study NCT03882346 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LifeLiver
Description: LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
Study NCT03579550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hysteroscopic metroplasty intervention arm
Description: One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
Study NCT04966884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK Inhibitor
Description: 1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months.
Study NCT02379520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 500mg/m\^2/day x 3 days (on days -4, -3 and -2)
Study NCT02379520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m\^2/day x 3 days (on days -4, -3, and -2)
Study NCT01047852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
Study NCT02379520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg every 2 weeks (+/- 3 days) starting on day -1
Study NCT02509637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flutter
Description: Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
Study NCT02509637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Compression
Description: Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
Study NCT02509637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT02509637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impulse Oscillometric
Description: For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks.
Study NCT02509637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dyspnea scale
Description: Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
Study NCT01160341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosteron
Description: Testosteron 250mg injection per 3-4 weeks for 6 months
Study NCT02509637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptability and tolerance
Description: patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High-flow Oxygen
Description: Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow Oxygen
Description: Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
Study NCT02509637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry
Description: During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
Study NCT02509637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Difficulty sputum
Description: Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-flow Oxygen
Description: Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow Oxygen
Description: Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
Study NCT00915564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
Study NCT00915564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
Study NCT01901081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMES
Description: Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months.
Study NCT03801512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
Study NCT03778242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
Study NCT03778242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Study NCT03010631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1: Lubiprostone Capsule, Fasted
Description: Lubiprostone soft gelatin capsule administered under fasted conditions
Study NCT03010631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Lubiprostone Capsule, Fasted
Description: Lubiprostone soft gelatin capsule administered under fasted conditions
Study NCT03010631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Study NCT03010631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Study NCT03010631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Lubiprostone Sprinkle Formulation, Fed
Description: Lubiprostone sprinkle formulation administered under fed conditions
Study NCT01400620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZN-6N4
Description: Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
Study NCT01400620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IZN-6N4
Description: Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
Study NCT00010608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Description: a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
Study NCT03801512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
Study NCT03801512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Inject investigators Platelet Rich Plasma at neuritis nerve roots
Study NCT03010631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Study NCT00411216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control exercises
Description: saccadic eye movements against a plain background; no head movements
Study NCT00411216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaze stabilization exercises
Description: adaptation and substitutin exercises encorporating retinal lsip and head movements
Study NCT02828943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMT with High Resistance EMT
Study NCT02828943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IMT with Low Resistance EMT
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP.664 gp140
Description: Administered by IM injection
Study NCT04426916 — intervention group
Intervention type: OTHER
Intervention: Spondylolisthesis
Description: Spondylolisthesis at a single level
Study NCT03244046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
Study NCT03244046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
Study NCT03244046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
Study NCT00010608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
Study NCT03863483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
Study NCT03863483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT03863483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT03863483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT03863483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study NCT03863483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
Study NCT04003584 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary bypass surgery
Description: Reviewed postoperative coronary bypass patients and compared postoperative pain levels
Study NCT03452072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Timolol gel with paraffin gauze dressings
Description: Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
Study NCT03452072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline dressing
Description: Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
Study NCT03606421 — intervention group
Intervention type: RADIATION
Intervention: SRS and neurocognitive assessments
Description: Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
Study NCT03606421 — intervention group
Intervention type: RADIATION
Intervention: WBRT and neurocognitive assessments
Description: Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
Study NCT04560465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
Study NCT04560465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
Study NCT03348917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.5% Povidone-Iodine [PVP-I]
Description: Betadine® 7.5% skin cleanser (PVP-I 7.5%)
Study NCT03348917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine skin cleanser
Description: Unity antiseptic hand wash (no alcohol)
Study NCT03348917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain non antibacterial soap
Description: Guardian gel hand wash (not medicated),
Study NCT02932332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow Air
Description: Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.